Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1001/archderm.1975.01630190121030 | DOI Listing |
Int J Rheum Dis
January 2025
Department of Internal Medicine, Hedi Chaker University Hospital, Sfax, Tunisia.
Int J Dermatol
January 2025
Department of Dermatology and Venereology, ULS São João, Porto, Portugal.
Int J Dermatol
January 2025
Department of Pathology, St. John's Medical College, Bangalore, India.
J Fr Ophtalmol
January 2025
Department of Ophthalmology, Basaksehir Cam and Sakura City Hospital, University of Health Sciences, 34480 Istanbul, Turkey.
Biomark Res
January 2025
Department of Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA.
FMS-like tyrosine kinase 3 (FLT3) genetic variants are commonly seen in high-grade myeloid neoplasms and are typically gain-of-function mutations associated with a proliferative disease phenotype. Inactivating FLT3 variants have been less frequently described in non-malignant, autoimmune disorders and are uncommon in aplastic anemia (AA). Herein, we report the first to our knowledge, and unusual case of a germline, gain-of-function, FLT3 variant in a patient with severe AA treated successfully with immunosuppressive therapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!